(Q38056525)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110469%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110469%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110469%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Johnson Stanslas

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110469%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Md Shariful Hasan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110469%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Lim Poh Hin

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110469%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

publication date

6 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110469%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Neuroscience

16 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110469%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

123

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110469%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110469%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

143-154

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110469%20AND%20SRC:MED&resulttype=core&format=json

Resistance to clopidogrel: a review of the evidence

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

21 January 2018

Clopidogrel resistance?

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

High on treatment platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Clopidogrel-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Clopidogrel resistance: role of body mass and concomitant medications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Platelet function monitoring in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Heart disease and stroke statistics--2011 update: a report from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Determinants of quality of life after stroke in China: the ChinaQUEST (QUality Evaluation of Stroke care and Treatment) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Prevalence of stroke among Chinese, Malay, and Indian Singaporeans: a community-based tri-racial cross-sectional survey

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: combined results of two Phase III, multicenter, randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Gastrointestinal complications of dual antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Gastrointestinal complications after 3 months of dual antiplatelet therapy for drug-eluting stents as assessed by wireless capsule endoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Optimizing clopidogrel therapy before stent implantation: should clinical setting be taken into account?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308

Adjusting clopidogrel loading doses according to vasodilator-stimulated phosphoprotein index: on time, too early, or too late?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00207454.2012.744308